This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (13)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology  • Hypersensitivity  • Dermatology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Hywel C. Williams, MSc, FRCP, PhD

Arch Dermatol. 1999;135:1530-1531.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate
Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ
Br J Dermatol. 1999;140:1114-1121

Atopic dermatitis (AD) affects approximately 2% of adults.¹ Adults may account for around 38% for all AD cases in a given community, and they often have more severe and persistent cases than their pediatric counterparts.¹ While many clinical trials of AD treatments (ie, topical corticosteroids) have evaluated the short-term efficacy (ie, reduction in erythema and scaling) and adverse effects (ie, stinging), hardly any have examined longer-term issues, such as overall control as measured by the prevention of relapses or the number and duration of disease-free periods.² This lack of trials is odd considering that AD is a chronic relapsing disease for the majority of patients who have it. It was refreshing, therefore, to read . . . [Full Text of this Article]

Editor's Comment

Nottingham, England

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Twice-Weekly Topical Corticosteroid Therapy May Reduce Atopic Dermatitis Relapses
Williams
Arch Dermatol 2004;140:1151-1152.
FULL TEXT  

What Proportion of Dermatological Patients Receive Evidence-Based Treatment?
Abeni et al.
Arch Dermatol 2001;137:771-776.
ABSTRACT | FULL TEXT